Question 1

What is Liraglutide?

Accepted Answer

Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). It was the first GLP-1 agonist approved specifically for weight loss and has the longest safety track record among the GLP-1 medication class.

Question 2

What are the research benefits of Liraglutide?

Accepted Answer

Research on Liraglutide has investigated its potential effects in several areas, including: FDA-approved for both diabetes (Victoza) and weight loss (Saxenda); Longest safety track record among GLP-1 medications; 5-10% body weight reduction in clinical trials; Studied for cardiovascular risk reduction (LEADER trial). These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does Liraglutide work?

Accepted Answer

Liraglutide is a modified GLP-1 analog (97% homology to human GLP-1) with a fatty acid chain that enables albumin binding, extending its half-life to ~13 hours. It activates GLP-1 receptors in the pancreas (enhancing insulin secretion), hypothalamus (reducing appetite and food intake), and GI tract (slowing gastric emptying).

Question 4

What is the FDA/legal status of Liraglutide?

Accepted Answer

Liraglutide is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is available for research use only. It has not been evaluated for safety or efficacy in humans by regulatory agencies. Always consult applicable laws in your jurisdiction before purchase or use.

Question 5

What are the known risks or side effects of Liraglutide?

Accepted Answer

Based on available research, Liraglutide has been associated with the following in study settings: Nausea (most common, especially at initiation); Diarrhea and constipation; Injection site reactions; Potential pancreatitis risk (rare). Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on Liraglutide?

Accepted Answer

Published research on Liraglutide can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "Liraglutide" or its aliases (Victoza, Saxenda) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

Liraglutide

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway.

A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.

Liraglutide attenuates doxorubicin-induced cardiomyocyte ferroptosis via DHHC7-mediated STAT3 palmitoylation.

Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOEmice.

Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer